Streetbeat News

PYPD

PolyPid Ltd.

https://www.polypid.com

Industry

Biotechnology

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Open

2.62

Mkt cap

17M

Volume

28K

High

2.75

P/E Ratio

-0.34

52-wk high

9.20

Low

2.37

Div yield

N/A

52-wk low

2.37

PolyPid Ltd. has announced a collaboration with ImmunoGenesis to develop new cancer immunotherapy formulations using PolyPid's PLEX Technology and ImmunoGenesis' STING agonist. This partnership aims to enhance treatments for solid tumors.

Portfolio Pulse from

December 11, 2024 | 12:15 pm

PolyPid Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement for continued listing. The company's equity is below the required $2.5 million, standing at approximately $2.158 million.

Portfolio Pulse from

November 29, 2024 | 6:15 pm

PolyPid Ltd. held its Q3 2024 earnings call, discussing financial results and company updates. Key participants included the CEO, COO, and CFO, with analysts from JMP and Craig-Hallum attending.

Portfolio Pulse from

November 13, 2024 | 7:15 pm

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company, will participate in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York. This event could provide the company with opportunities to engage with investors and potentially impact its stock price.

Portfolio Pulse from

November 07, 2024 | 12:15 pm

PolyPid published a full dataset from its first Phase 3 study of D-PLEX100 in the International Journal of Surgery. The SHIELD I study, one of the largest in over a decade for SSI prevention in colorectal resection, showed potential benefits for high-risk patients. The ongoing SHIELD II study focuses on large surgical incisions, with results expected in Q1 2025.